Tenaya Therapeutics, Inc. (TNYA)

NASDAQ: TNYA · IEX Real-Time Price · USD
2.12
-0.17 (-7.42%)
At close: Dec 9, 2022 4:00 PM
2.13
+0.01 (0.47%)
After-hours: Dec 9, 2022 5:51 PM EST
-7.42%
Market Cap 146.53M
Revenue (ttm) n/a
Net Income (ttm) -116.30M
Shares Out 41.36M
EPS (ttm) -3.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 145,500
Open 2.26
Previous Close 2.29
Day's Range 2.04 - 2.26
52-Week Range 1.73 - 22.87
Beta n/a
Analysts Buy
Price Target 26.01 (+1,126.9%)
Earnings Date Nov 9, 2022

About TNYA

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart fa... [Read more]

Industry Biotechnology
IPO Date Jul 30, 2021
Employees 140
Stock Exchange NASDAQ
Ticker Symbol TNYA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for TNYA stock is "Buy." The 12-month stock price forecast is 26.01, which is an increase of 1,126.89% from the latest price.

Price Target
$26.01
(1,126.89% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentiall...

2 days ago - GlobeNewsWire

Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy ...

TN-401 is being developed for the treatment of genetic arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by mutations in the PKP2 gene

1 week ago - GlobeNewsWire

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentiall...

2 weeks ago - GlobeNewsWire

Tenaya Therapeutics Announces Closing of Public Offering

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentiall...

2 weeks ago - GlobeNewsWire

Tenaya Therapeutics Announces Pricing of Public Offering

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentiall...

3 weeks ago - GlobeNewsWire

Tenaya Therapeutics Announces Proposed Public Offering

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentiall...

3 weeks ago - GlobeNewsWire

Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ...

SOUTH SAN FRANCISCO, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentiall...

2 months ago - GlobeNewsWire

Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potential...

2 months ago - GlobeNewsWire

Does Tenaya Therapeutics, Inc. (TNYA) Have the Potential to Rally 368% as Wall Street Analysts Expect?

The consensus price target hints at a 367.7% upside potential for Tenaya Therapeutics, Inc. (TNYA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e...

3 months ago - Zacks Investment Research

Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Received State Licensing to Enable cGMP Manufacturing of Drug Product

3 months ago - GlobeNewsWire

Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibit...

Tenaya's Precision Medicine Platform Used to Identify HDAC6 Target Using Phenotypic Screening and Machine Learning Algorithms

5 months ago - GlobeNewsWire

Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of P...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics today announced that it has completed the build-out and operational launch of its Genetic Medicines Manufacturing Center.

5 months ago - Business Wire

Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Fai...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics announced that it will present preclinical data at the European Society of Cardiology (ESC) Heart Failure 2022 conference.

6 months ago - Business Wire

Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics today provided business and program updates, and reported financial results for the first quarter ended March 31, 2022.

6 months ago - Business Wire

Tenaya Therapeutics to Present Preclinical Data on Gene Therapy Programs and Platform Capabilities at the American So...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics announces its presentations at the ASGCT 25th Annual Meeting, taking place May 16–19, 2022.

7 months ago - Business Wire

Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at Heart Rhythm 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics announced that it will present new preclinical data at the Heart Rhythm Society's upcoming annual Heart Rhythm 2022 meeting.

7 months ago - Business Wire

Tenaya Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics today announced participation in two upcoming investor conferences.

8 months ago - Business Wire

Tenaya Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics provided business and program updates, and reported financial results for the fourth quarter and year-end 2021.

8 months ago - Business Wire

Why Earnings Season Could Be Great for Tenaya Therapeutics (TNYA)

Tenaya Therapeutics (TNYA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

10 months ago - Zacks Investment Research

Tenaya Therapeutics Provides 2022 Business Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics provided a 2022 business update.

10 months ago - Business Wire

Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics today announced changes to its Board of Directors.

1 year ago - Business Wire

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics announced today that Faraz Ali, Chief Executive Officer, will participate in the 33rd Annual Piper Sandler Healthcare Conference.

1 year ago - Business Wire

Tenaya Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics today reported business and program updates and third quarter 2021 financial results.

1 year ago - Business Wire

Tenaya Therapeutics to Present Preclinical Data on Its Gene Therapy Programs at the ESGCT 28th Annual Congress

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics announced today that it will present new preclinical data at the ESGCT 28th Annual Congress.

1 year ago - Business Wire

Tenaya Therapeutics to Participate in Upcoming Investor and Industry Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $TNYA--Tenaya Therapeutics announced today that Faraz Ali, Chief Executive Officer, will participate in upcoming investor and industry conferences.

1 year ago - Business Wire